Published in Neuropharmacology on October 06, 2017
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") Lancet (1992) 7.01
Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction (2011) 3.42
The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev (2003) 3.35
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol (2005) 3.30
A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol (2012) 2.33
Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Hum Psychopharmacol (2013) 2.28
Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs (1987) 2.20
Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther (1994) 1.64
Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry (2007) 1.62
Free radicals and the pathobiology of brain dopamine systems. Neurochem Int (1998) 1.60
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol (2003) 1.47
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (2010) 1.43
Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol (2009) 1.42
State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci (1990) 1.42
Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry (2010) 1.39
The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol (2002) 1.37
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol (2012) 1.31
Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology (2005) 1.30
The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess (2009) 1.24
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther (2011) 1.22
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology (2000) 1.21
Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology (2000) 1.19
From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders. Neurobiol Learn Mem (2013) 1.19
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One (2012) 1.13
Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol (2001) 1.13
In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol (1987) 1.08
MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci (2013) 1.07
Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol (1986) 1.06
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology (1998) 1.05
(+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. Eur J Pharmacol (2000) 1.00
Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther (2010) 0.95
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci (2011) 0.95
Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology (2008) 0.94
The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev (2015) 0.92
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry (2015) 0.91
The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis. Curr Neuropharmacol (2011) 0.90
Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain Res (2008) 0.89
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry (2016) 0.87
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry (2011) 0.87
Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse (2008) 0.86
Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. Hum Exp Toxicol (2010) 0.84
Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology (1990) 0.84
MDMA (N-methyl-3,4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol Biochem Behav (2007) 0.82
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J Med Chem (1990) 0.81
Effects of MDMA on body temperature in humans. Temperature (Austin) (2014) 0.80
Relevance of MDMA ("ecstasy")-induced neurotoxicity to long-lasting psychomotor stimulation in mice. Psychopharmacology (Berl) (2003) 0.80
Neuroimaging in moderate MDMA use: A systematic review. Neurosci Biobehav Rev (2015) 0.78
Absolute configuration and psychotomimetic activity. NIDA Res Monogr (1978) 0.78
Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Psychopharmacology (Berl) (2013) 0.78
Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice. Eur Neuropsychopharmacol (2014) 0.78
Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations. Int J Neuropsychopharmacol (2012) 0.78
The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness. Neuropsychopharmacology (2017) 0.76
Professor Miloslav Krsiak 1939 - 2016. Psychopharmacology (Berl) (2016) 0.76
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem (2012) 0.76
Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther (2015) 0.76
Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol (2017) 0.76
3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner. Neuropsychopharmacology (2017) 0.75
Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl) (2017) 0.75